Strategic Expansion Regis Technologies is now part of ESTEVE CDMO with a recent expansion in Morton Grove, Illinois and ongoing facility growth in Celrà, Spain and Girona, Spain. This indicates increasing capacity and potential for expanding small-molecule API production collaborations, especially for high-potency containment projects and scale-up efforts in North America and Europe.

Integrated CDMO As part of ESTEVE CDMO, Regis leverages end-to-end small-molecule API development and manufacturing, including advanced chromatography through the Regis Chromatography brand. This creates opportunities to position Regis as a one-stop shop for pharma/biotech partners seeking streamlined development-to-commercialization services.

High-Containment Capabilities Recent facility expansions emphasize spray drying capacity and high-potency containment suites. This aligns well with clients needing containment-secure processing for potent APIs and advanced intermediates, presenting cross-sell opportunities into existing ESTEVE CDMO customers and new high-potency programs.

North America Growth Acquisition and expansion in Morton Grove signal strengthening of the U.S. footprint to support U.S. and North American market needs. There is potential to pursue local partnerships, faster tech transfer, and regional regulatory alignment for post-Phase I to commercial-scale programs.

Financial Footing With reported revenue between 50 and 100 million and a growing global footprint, Regis/ESTEVE CDMO presents a credible platform for mid-market pharma and biotech companies seeking reliable API supply, advanced manufacturing, and scale-up capabilities with international compliance and established quality standards.